Biopharmaceutical company Elusys Therapeutics, Inc., which specializes in developing biodefense countermeasures, has announced that the U.S. government has
awarded it a contract to develop an anti-toxin for pre-and post-exposure prophylaxis (PEP) use via intramuscular injection.
We’ve updated our Privacy Policy to make it clearer how we use your personal data. Please read our Cookie Policy to learn how we use cookies to provide you with a better experience.